



Pearl Therapeutics Named Winner of 2013 TiE50 “Top Startup” at TiEcon 2013

May 30, 2013 -- REDWOOD CITY, CALIF -- Pearl Therapeutics, Inc. announced today that it has been named *Winner of 2013 [TiE50](#) “Top Startup” Award at [TiEcon 2013](#)* for a third time. Pearl was amongst 50 winners honored at TiEcon, the world’s largest conference for entrepreneurs.

“The TiE organization’s recognition of Pearl is yet another validation of the accomplishments our scientists have made in the field of pulmonary drug product and technology development,” said [Chuck Bramlage](#), Pearl’s chief executive officer. “Our patented technology has led to the development of valuable treatments for COPD, including a fixed-dose combination bronchodilator in Phase 3, and a very innovative triple combination therapy. Even as we enter late stages of product development, we remain committed to the principles that have guided us to date: capital efficiency, development proficiency and an entrepreneurial spirit.”

Speaking to a global audience at the awards ceremony during TiEcon 2013, the conference chairman and president of TiE Silicon Valley, Mr. Venkatesh Shukla said that “the TiE50 program screened 1142 companies from 24 countries and 50 best-of-breed companies were announced winners.”

“Over the past four years, the TiE50 program has gained global acclaim attracting startups from all over the world. TiE50 as a brand has gained much recognition amongst the VC and Angel communities – particularly in Silicon Valley. About 110 finalists and winners had successful exits” said program chair Ram K. Reddy.

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl’s proprietary porous particle co-suspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare Partners. For more information, please visit www.pearltherapeutics.com.

About TiE50

TiE50 is TiE Silicon Valley’s premier annual awards program keenly contested by thousands of technology startups worldwide. Awards are announced at TiEcon, the world’s largest conference for entrepreneurs. TiE is a global, not-for-profit network of entrepreneurs and professionals dedicated to the advancement of entrepreneurship. TiE provides a platform for mentoring, networking and education for technology entrepreneurs worldwide. Our global network of 54 chapters located in most major North American, Asian and European countries and cities with more than 14,000 members across 13 countries.

About TiEcon

TiEcon is the world’s largest conference for entrepreneurs and intrapreneurs with loyal participation from top technology companies, leading venture capital firms, and global service providers. TiEcon 2013 attracted 3,700+ attendees from across the world -- including CEOs of established companies to first-time entrepreneurs creating new companies, to leading investment professionals and corporate executives. TiEcon was listed by Worth Magazine in their September 2011 issue to be among the 10 Best Conferences for Ideas and Entrepreneurship along with TED and the World Economic Forum. For more information on TiEcon, visit <http://www.tiecon.org/>.

###

Contacts for Pearl Therapeutics: Noreen McKiernan
Pearl Therapeutics
(650) 305-2609
nmckiernan@pearltherapeutics.com

Aline Schimmel
Scienta Communications
(312) 238-8957
aschimmel@scientapr.com